Jefferies Group Comments on Enzymotec Ltd.’s Q3 2017 Earnings (ENZY)

Enzymotec Ltd. (NASDAQ:ENZY) – Jefferies Group lifted their Q3 2017 earnings per share (EPS) estimates for shares of Enzymotec in a report released on Wednesday. Jefferies Group analyst L. Alexander now anticipates that the biotechnology company will post earnings of $0.02 per share for the quarter, up from their prior forecast of $0.01. Jefferies Group has a “Hold” rating and a $8.00 price target on the stock.

Enzymotec (NASDAQ:ENZY) last released its quarterly earnings results on Wednesday, May 17th. The biotechnology company reported $0.03 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.06 by $0.03. Enzymotec had a negative net margin of 9.50% and a negative return on equity of 2.06%. The business had revenue of $12 million for the quarter, compared to the consensus estimate of $14.23 million. During the same period last year, the firm posted $0.09 EPS. The business’s quarterly revenue was down 14.3% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: “Jefferies Group Comments on Enzymotec Ltd.’s Q3 2017 Earnings (ENZY)” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/07/19/jefferies-group-comments-on-enzymotec-ltd-s-q3-2017-earnings-enzy-updated-updated-updated.html.

Separately, Zacks Investment Research lowered shares of Enzymotec from a “hold” rating to a “strong sell” rating in a research report on Wednesday, March 1st.

Enzymotec (NASDAQ ENZY) opened at 8.00 on Friday. The company’s 50 day moving average is $8.24 and its 200-day moving average is $8.15. Enzymotec has a 1-year low of $5.20 and a 1-year high of $9.32. The firm’s market cap is $183.19 million.

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of Enzymotec by 38.9% in the first quarter. Geode Capital Management LLC now owns 14,383 shares of the biotechnology company’s stock worth $126,000 after buying an additional 4,028 shares during the last quarter. State of New Jersey Common Pension Fund D raised its position in shares of Enzymotec by 12.5% in the first quarter. State of New Jersey Common Pension Fund D now owns 28,110 shares of the biotechnology company’s stock worth $247,000 after buying an additional 3,113 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Enzymotec by 3.2% in the first quarter. Acadian Asset Management LLC now owns 237,184 shares of the biotechnology company’s stock worth $2,088,000 after buying an additional 7,322 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Enzymotec by 12.3% in the fourth quarter. Renaissance Technologies LLC now owns 290,000 shares of the biotechnology company’s stock worth $1,900,000 after buying an additional 31,700 shares during the last quarter. Finally, State Street Corp raised its position in shares of Enzymotec by 4.7% in the fourth quarter. State Street Corp now owns 19,944 shares of the biotechnology company’s stock worth $131,000 after buying an additional 890 shares during the last quarter. Institutional investors own 30.33% of the company’s stock.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply